Redeye comments on further news from the all-important US market.
Redeye finetunes its forecasts for 2025 and beyond following Fortnox’s price increases.
Vitrolife continues stabilise its growth rate and is approaching high single-digit growth.
Redeye comments on Evolution’s Q4-results which were in line with our forecasts.
Redeye offers a preview of Doro's Q4 results set to be released on February 13.
Redeye comments on Embracer’s preliminary Q3-results which came in stronger than expected, driven ma...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, toget...
38% y-o-y sales growth for Catalyst in Q4'24e We leave our EBIT forecasts unchanged ahead of the rep...
Taaleri Real Estate and Keva (Finland’s largest pension insurer, responsible for providing pensions ...
Cost-effective coatings for hydrogen and metallisation applications Seizing opportunities in Chinese...
We forecast Q4 revenue of NOK 243m, +15% y-o-y Doro acquisition closed, could lift '28e EBITA by ~12...
Q4'24e organic sales growth of 24% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye comments on the outcome of Ngenic’s rights issue, which was subscribed to 88%, injecting Ngen...
According to preliminary information, annual EBITDA will be EUR 4-6m in 2024 (old guidance EUR 4-8m,...
In Q4-24, Eevia Health Plc (publ) (“Eevia” or “the Company”) launched a transformational restructuri...
